Ma M, Ma X, Chang J, Yin F, Ma S, Zhang Y
Front Endocrinol (Lausanne). 2023; 14:1192108.
PMID: 37654567
PMC: 10465363.
DOI: 10.3389/fendo.2023.1192108.
Balogh E, Perez-Nieves M, Cao D, Hadjiyianni I, Ashraf N, Desai U
Diabetes Ther. 2020; 11(8):1735-1744.
PMID: 32562245
PMC: 7376995.
DOI: 10.1007/s13300-020-00856-4.
Ji L, Gao L, Chen L, Wang Y, Ma Z, Ran X
EClinicalMedicine. 2020; 23:100368.
PMID: 32529176
PMC: 7283138.
DOI: 10.1016/j.eclinm.2020.100368.
Lim A, Song Y
Nurs Open. 2020; 7(3):887-894.
PMID: 32257276
PMC: 7113521.
DOI: 10.1002/nop2.462.
Song Y, Ku B, Cho J, Jun Y, Kim B, Nam S
Ann Transl Med. 2020; 7(23):760.
PMID: 32042776
PMC: 6989974.
DOI: 10.21037/atm.2019.11.77.
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Vilsboll T, Ekholm E, Johnsson E, Garcia-Sanchez R, Dronamraju N, Jabbour S
Diabetes Obes Metab. 2020; 22(6):957-968.
PMID: 32003150
PMC: 7317718.
DOI: 10.1111/dom.13981.
The Mediating Role of Diabetes Distress and Depressive Symptoms in Type 2 Diabetes Medication Adherence Gender Differences.
Aronson B, Sittner K, Walls M
Health Educ Behav. 2019; 47(3):474-482.
PMID: 31665927
PMC: 7341960.
DOI: 10.1177/1090198119885416.
The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran.
Shafie Pour M, Sadeghiyeh T, Hadavi M, Besharati M, Bidaki R
Diabetes Metab Syndr Obes. 2019; 12:1349-1354.
PMID: 31496772
PMC: 6689560.
DOI: 10.2147/DMSO.S200867.
The perceived barriers to insulin therapy among type 2 diabetic patients.
Hussein A, Mostafa A, Areej A, Mona A, Shimaa A, Najd A
Afr Health Sci. 2019; 19(1):1638-1646.
PMID: 31148993
PMC: 6531943.
DOI: 10.4314/ahs.v19i1.39.
Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom.
Brod M, Basse A, Markert M, Pfeiffer K
Diabetes Ther. 2019; 10(4):1323-1336.
PMID: 31127490
PMC: 6612333.
DOI: 10.1007/s13300-019-0636-0.
Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients.
Pfeiffer K, Basse A, Lee X, Waldman L
Diabetes Ther. 2018; 9(5):1931-1944.
PMID: 30120755
PMC: 6167294.
DOI: 10.1007/s13300-018-0487-0.
GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice.
Al Mansari A, Obeid Y, Islam N, Fariduddin M, Hassoun A, Djaballah K
BMJ Open Diabetes Res Care. 2018; 6(1):e000519.
PMID: 30023075
PMC: 6045741.
DOI: 10.1136/bmjdrc-2018-000519.
The Barbados Insulin Matters (BIM) study: Barriers to insulin therapy among a population-based sample of people with type 2 diabetes in the Caribbean island of Barbados.
Taylor Jr C, Taylor G, Atherley A, Hambleton I, Unwin N, Adams O
J Clin Transl Endocrinol. 2017; 8:49-53.
PMID: 29067259
PMC: 5651331.
DOI: 10.1016/j.jcte.2017.04.002.
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Jarvinen H
Diabetes Obes Metab. 2017; 20(3):541-548.
PMID: 28862801
PMC: 5836995.
DOI: 10.1111/dom.13105.
Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures.
Holmes-Truscott E, Pouwer F, Speight J
Curr Diab Rep. 2017; 17(7):46.
PMID: 28508930
DOI: 10.1007/s11892-017-0873-4.
Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.
Sambamoorthi U, Garg R, Deb A, Fan T, Boss A
Curr Med Res Opin. 2017; 33(7):1309-1316.
PMID: 28393573
PMC: 5520976.
DOI: 10.1080/03007995.2017.1318121.
Fear of Self-Injecting and Self-Testing and the Related Risk Factors in Adolescents with Type 1 Diabetes: A Cross-Sectional Study.
Al Hayek A, Robert A, Babli S, Almonea K, Al Dawish M
Diabetes Ther. 2016; 8(1):75-83.
PMID: 27995595
PMC: 5306120.
DOI: 10.1007/s13300-016-0221-8.
Anxiety and Depressive Symptoms as Predictors of All-Cause Mortality among People with Insulin-Naïve Type 2 Diabetes: 17-Year Follow-Up of the Second Nord-Trøndelag Health Survey (HUNT2), Norway.
Iversen M, Nefs G, Tell G, Espehaug B, Midthjell K, Graue M
PLoS One. 2016; 11(8):e0160861.
PMID: 27537359
PMC: 4990320.
DOI: 10.1371/journal.pone.0160861.
Association of more negative attitude towards commencing insulin with lower glycosylated hemoglobin (HbA1c) level: a survey on insulin-naïve type 2 diabetes mellitus Chinese patients.
Fu S, Wong C, Chin W, Luk W
J Diabetes Metab Disord. 2016; 15:3.
PMID: 26913243
PMC: 4765059.
DOI: 10.1186/s40200-016-0223-0.
Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes.
Song S, Hwang Y, Ahn K, Cha B, Song Y, Lee D
Diabetes Ther. 2015; 6(4):547-558.
PMID: 26515457
PMC: 4674476.
DOI: 10.1007/s13300-015-0140-0.